



सत्यमेव जयते

GOVERNMENT OF INDIA  
CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION (Headquarter)  
(Directorate General of Health  
Services) Ministry of Health & Family  
Welfare  
FDA Bhavan  
ITO, Kotla Road  
New Delhi - 110002 (Delhi)  
Phone No.: 91-11-  
23216367  
Fax No.: 91-11-23236973  
E-Mail : dci@nic.in

**File No. CT/24/000096**

To,

M/s Parexel International Clinical Research Private Limited,  
CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A,  
Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103

Sir,

With reference to your application No. GCT/CT04/FF/2024/44486 dated 23-JUL-2024, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)” Protocol No. D516KC00001, Version 1.0 dated 26-Mar-2024 with a total of up-to 39 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019**

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- 1) Investigator should be Medical Oncologist only.
- 2) More geographically distributed Govt. sites shall be included in the study.
- 3) Human biological samples i.e. Whole blood, plasma, serum and tumor tissue related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.
- 4) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- 5) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- 6) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- 7) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- 8) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- 9) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- 10) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- 11) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- 12) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- 13) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- 14) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- 15) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- 16) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- 17) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- 18) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- 19) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- 20) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- 21) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- 22) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licensing Authority  
Stamp

**FORM CT-06**

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. Parexel International Clinical Research Private Limited, CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A, Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103 Telephone No.: 8067723000 FAX: 80 67723001 E-Mail : PAREXELINDIA@PAREXEL.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No. D516KC00001, Version 1.0 dated 26-Mar-2024** in the below mentioned clinical trial sites [As per Annexure].-
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date \_\_\_\_\_

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licensing Authority  
Stamp

**Note:** The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

**Annexure:**

Details of new drug or investigational new drug:

<b>Names of the new drug or investigational new drug</b>	Datopotamab Deruxtecan (DATO-DXD, DS-1062) and Osimertinib
	Datopotamab Deruxtecan (DATO-DXD, DS-1062) and Osimertinib
	Datopotamab Deruxtecan (DATO-DXD, DS-1062) and Osimertinib
<b>Therapeutic class:</b>	Antibody drug conjugate Tyrosine kinase inhibitor
	Antibody drug conjugate Tyrosine kinase inhibitor
	Antibody drug conjugate Tyrosine kinase inhibitor
<b>Dosage form:</b>	Tablets, Lyophilised powder Concentrate solution infusion
	Tablets, Lyophilised powder Concentrate solution infusion
	Tablets, Lyophilised powder Concentrate solution infusion
<b>Composition:</b>	DS-1062a =100.0000 milligram(mg) In House Specification Active
	Osimertinib =80.0000 milligram(mg) In House Specification Active
	Osimertinib =40.0000 milligram(mg) In House Specification Active
<b>Indications:</b>	Locally Advanced or Metastatic Non-Small Cell Lung Cancer
	Locally Advanced or Metastatic Non-Small Cell Lung Cancer
	Locally Advanced or Metastatic Non-Small Cell Lung Cancer

**Annexure:**

Details of clinical trial site:

<b>S.No.</b>	<b>Names and address of clinical trial site</b>	<b>Ethics committee details</b>	<b>Name of investigator</b>
1.	Regional Cancer Centre, PO Box No. 2417, Medical College Campus Thiruvananthapuram Kerala - 695011	Human Ethics Committee, First floor, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram, Kerala – 695011, India.  EC Re-Registration No ECR/21/Ins/Ker/2013/RR-19	Dr Anoop T M
2.	Kohlapur Cancer Center Situated at R-S238, Gokul Shirgaon, Karveer, Kohlapur Maharashtra – 416234 India.	Institutional Ethics Committee (IEC) Kolhapur Cancer Centre (KCC) A/p. R. S. No. 238, opp. Mayur Petrol Pump, Gokul Shirgaon, Kolhapur, Maharashtra-416234 India.  EC Re-Registration No ECR/523/Inst/MH/2014/RR-20	Dr Nilesh Ashok Dhamne
3.	All India Institute of Medical Sciences, situated at Village Sijua, Patrapada, PO Dumduma, Bhubaneswar Orissa - 751019	Institutional Ethics Committee, AIIMS Bhubaneswar, All India Institute of Medical Sciences, BBSR, AIIMS Bhubaneswar, Sijua, P/O, Patrapada, Bhubaneswar, Khordha, Orissa - 751019, India. EC Re-Registration No	Dr Deepak Kumar Das

		ECR/534/Insta/OD/2014/RR-20	
4.	Thangam Hospital and Thangam Cancer Center, No. 54, Dr Sankaran Road Namakkal Namakkal Tamil Nadu - 637001 India.	Thangam Hospital - Institutional Ethics Committee Thangam Hospital No. 54, Dr Sankaran Road Namakkal Namakkal Tamil Nadu - 637001 India.  EC Re-Registration No ECR/1069/INST/TN/2018/RR-21	Dr Bhavesh Poladia
5.	Grant Medical Foundation Ruby Hall Clinic, 40, Sassoon Road, Pune- 411001, Maharashtra, India	Institutional Ethics committee Poona Medical Research Foundation Ruby Hall Clinic 40, Sassoon Road Pune Maharashtra - 411001 India.  EC Re-Registration No ECR/24/Inst/MH/2013/RR-22	Dr Minish Jain
6.	Bharath Hospital and Institute of Oncology, NO. 438, 1 <sup>st</sup> Stage, Outer ring road Hebbal Industrial Area Lakshmikanth Nagar Karnataka - 570017	IEC-BHIO- Bharath Hospital & Institute of Oncology, #438, Outer Ring Road, Hebbal, Mysuru-570017, India.  EC Re-Registration No ECR/994/Inst/KA/2017/RR-21	Dr Srinivas K G
7.	SANJEEVANI CBCC USA CANCER HOSPITAL , FRONT OF JAIN MANDIR DAWADA COLONY PACHPEDI NAKA RAIPUR Chhattishgarh - 492001	Sanjeevani Cancer Hospital Ethics Committee, Sanjeevani CBCC USA Cancer Hospital, In front of Jain Mandir Dawada Colony, Pachpedi Naka Raipur, 492001, Chhattisgarh, India.  EC Re-Registration No: ECR/818/INST/CG/2016/RR-19	Dr Rakesh Mishra
8.	Sujan surgical cancer hospital And ACF, 52 B, Shankar nagar, Main Road, Amravati Amravati Maharashtra - 444606	Amravati Ethics Committee Sujan Surgical Cancer Hospital and Research 52/B Shankar Nagar Main Road Amravati, Maharashtra - 444606 India.  EC Re-Registration No ECR/432/Inst/MH/2013/RR-19	Dr Rajender Singh Arora
9.	Basavatarakam Indo American Cancer Hospital and Research Institute, Road No 10, Banjara hills, Hyderabad Telangana - 500034	Institutional Ethics Committee Basavatarakam Indo American Cancer Hospital RI ROAD # 10 Banjara Hills Hyderabad	Dr Ayyagari Santa

		Telangana - 500034 India EC Re-Registration No ECR/7/Inst/AP/2013/RR-20	
10.	Bhaktivedanta Hospital and Research Institute, 3 <sup>rd</sup> Floor, Medical Research Department. Srishti Complex, Bhaktivedanta Swami Marg, Mira Road East Thane	Bhaktivedanta Hospital Ethics Committee, 3rd Floor, Medical Research Department. Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (East) Thane-401107  EC Re-Registration No EC/396/Inst/MH/2013/RR-24	Dr Nirmal Raut
11.	GBH General Hospital and BH Memorial Cancer Hospital, Near Transport Nagar, Airport Road, Bedwas, Udaipur-. Udaipur Rajasthan - 313002	Ethics Committee GBH memorial Cancer Hospital, Near Transport Nagar, Airport Road, Bedwas, Udaipur -313002.  EC Re-Registration No: ECR/1099/Inst/RJ/2018/RR-21	Dr Rohit Dominic Jawahar Rebello

\*\*\*\*\*